Costly $20M offering gives Alexza a chance for FDA and EMA approvals
This article was originally published in Scrip
Executive Summary
Investors placed bets on 16 February on whether Alexza Pharmaceuticals could get its inhaled antipsychotic drug Adasuve approved either in the US or European Union when they bought into the Mountain View, California-based company at $0.50 per share, the stock's lowest price in the past year.